TIMI 15A evaluated the pharmacodynamic response, safety and pharmacokinetics of various doses of the GP IIb/IIIa inhibitor RPR 109891 given intravenously for the treatment of patients with acute coronary syndromes.
MAIN RESULTS:
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials
Am Heart J. 2000 Jul;140(1):81-93.